# 12 / 48 Week Pivotal PFT vs PBO in COPD I

> **NCT00782210** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 625 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Olodaterol (BI1744)
- **DRUG:** Olodaterol (BI1744)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00782210
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-09
- **Final completion:** —
- **Target enrollment:** 625 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782210, "12 / 48 Week Pivotal PFT vs PBO in COPD I". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00782210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*